

ASX ANNOUNCEMENT

11 March 2020

WHEEZOS IN CHINESE HOSPITALS

Respiri Limited (ASX:RSH) ("Respiri" or the "Company") would like to advise the following.

The Company has agreed to a request by three hospitals in China to trial wheezos on patients admitted with heightened respiratory problems resulting from infection with the coronavirus COVID19.

Three hospitals under the supervision of the Chongqing Municipal Health Commission have expressed their interest in using Respiri's wheezo device to help monitor the lung function of patients who have been admitted with the COVID19 virus. The hospitals are:

- People's Hospital of Dadukou District (three devices)
- People's Hospital of Banan District (three devices), and
- People's Hospital of Double River New Zone (four devices)

For humanitarian reasons the Company has agreed to assist and deliver the requested devices accordingly. This is not part of a formal trial nor does it represent any form of pivot in the Company's strategy to focus on coronaviruses. But if the device can help with remote monitoring of affected asthma families at this time then the Company is happy to assist in any way it can.



Alastair Beard
Company Secretary

This ASX announcement dated 11 March 2020
has been authorised for release by the Board of Directors of Respiri Limited.

---End---

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.